[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615123":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":31,"collaborators":10,"id":33,"slug":10,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"patients with CLL",null,"no control group or comparator involved",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":10},"Research Site","RECRUITING","Minsk","Belarus","BY",{"type":26,"coordinates":27},"Point",[28,29],27.56653,53.90019,{"lat":29,"lon":28},{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100615123",false,"NCT07288515","Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus","Observational Prospective Study of Acalabrutinib in Chronic Lymphocytic Leukemia Therapy in Real Clinical Practice in Belarus.","ALICIA(BY)","Inclusion Criteria:\n\n* Age ≥18 years.\n* Confirmed diagnosis of CLL.\n* Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation.\n* Treatment-naïve or R\u002FR CLL.\n* Ability and willingness to provide informed consent for study participation.\n\nExclusion Criteria:\n\n* Patients not satisfying any of the inclusion criteria.\n* Prior treatment with any BTK inhibitor.\n* Participation in other ongoing clinical trials.\n* Pregnant or breastfeeding females","ALL","18 Years",{"count":43,"type":44},50,"ESTIMATED","OBSERVATIONAL","to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL",[48],"Chronic Lymphocytic Leukemia",[50],"CLL","2026-06-12",{"date":53,"type":54},"2026-06-15","ACTUAL",{"date":56,"type":54},"2025-12-31",{"date":58,"type":44},"2029-12-31",{"name":5,"class":6},1]